Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Day One Biopharmaceuticals, Inc. - Common Stock (NQ:DAWN)

7.180 +0.140 (+1.99%)
Streaming Delayed Price Updated: 11:07 AM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Day One Biopharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
Why Astera Labs Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Earnings Scheduled For August 5, 2025
 
Via Benzinga
Earnings Scheduled For May 6, 2025
 
Via Benzinga
Earnings Scheduled For February 25, 2025
 
Via Benzinga
Day One (DAWN) Q2 Revenue Jumps 313%
Via The Motley Fool
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Day One Biopharmaceuticals Inc (NASDAQ:DAWN) Reports Q2 2025 Earnings: Revenue Growth but Wider-Than-Expected Loss
Day One Biopharmaceuticals reports Q2 2025 earnings with revenue growth but wider-than-expected loss, causing an 11.8% stock drop. OJEMDA sales rise 10% QoQ, while pipeline advances. 
Via Chartmill
Day One Reports Second Quarter 2025 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Reports First Quarter 2025 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Biotech Investing: How PRV’s Can Unlock Major Opportunities (OSTX, DAWN, SWTX, PTCT)
Via AB Newswire
Biotech Investing: How PRVs Can Unlock Major Opportunities
Biotech Investing: How PRVs Can Unlock Major Opportunities 
Via News Direct
Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate Priorities
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Day One Reports Third Quarter 2024 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Bank of America Says Buy These 3 Stocks for a Double-Digit Rally
Despite fears of a recession roiling the markets, analysts say these are the best stocks to buy with an average upside potential of 72%. 
Via InvestorPlace
Topics Economy
Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
DAWN Stock Earnings: Day One Biopharmaceutical Beats EPS, Beats Revenue for Q2 2024
DAWN stock results show that Day One Biopharmaceutical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Oversubscribed $175.0 Million Private Placement
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.